Association Between Plasminogen Activator Inhibitor-1-675 4g/5g Insertion/deletion Polymorphism And Chronic Obstructive Pulmonary Disease | 86560
Journal of Molecular and Genetic Medicine
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Molecular pathology of chronic obstructive pulmonary disease (COPD) is still being investigated to discover relationships with disease pathogenesis. Evidence of plasminogen activator inhibitor-1 (PAI-1) overexpression in the sputum and the blood of COPD patients is growing. We aimed to investigate the potential relation between PAI-1 promoter 4G/5G insertion/ deletion polymorphism and COPD development. In a case-control study, we genotyped 117 COPD patients and 160 control subjects for PAI-1 promoter 4G/5G polymorphism by an allele-specific polymerase chain reaction analysis. All subjects were male smokers. In the co-dominant model, there was a significant difference in the distribution of 5G/5G, 4G/5G and 4G/4G genotypes between COPD patients and controls (p=0.002). In the recessive model, carriers of 4G/4G genotype were significantly higher in COPD patients than controls (p=0.01). Carriers of 4G/4G genotype were at higher risk to develop COPD than those carrying 5G/5G or 4G/5G genotypes (crude odds ratio (OR)=2.10, 95% confidence interval (CI)=1.19-3.73, adjusted OR=2.5, 95% CI=1.22-3.99). PAI-1 4G/5G genetic variations are associated with COPD development in males. [email protected]
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals